Austerity measures brought in to tackle the debt crisis are affecting frontline healthcare services in many countries, particularly in the complex, expensive field of oncology. Cancer World asked readers to share their first-hand experiences. Doctors [more]
Implement guidelines, adopt what works and reject what doesn’t, focus on cost-effectiveness–there are so many ways cancer care could be improved. Mary Gospodarowicz, believer, pragmatist and ‘raving optimist’, is determined to make it happen. Implement [more]
Too toxic, too untargeted, too difficult to prove. These assumptions about chemoprevention are being challenged by important developments in the search for preventive options tailored to specific risk factors in breast cancer. Recent years have [more]
Often mistaken for a radiotherapist or medical oncologist, this expert in voice-box sparing strategies has reached out to a wide variety of professionals– most recently actors– in his quest to improve the chances of patients [more]
Cancer patients who do not share their doctors’ belief in the drug they are prescribed, or find living with the side-effects hard to bear, may fail to take their pills according to the prescription– and [more]
This editorial argues that handling the transition from active to palliative care is indeed a weak point in oncology, and if the cancer community fails to address it, we will leave it open to the [more]
She’s an internationalist, she believes in quality control and she’s not afraid of a bit of friction. Who better, then, to lead the project to define standards for Europe’s cancer centres and sort the centres [more]
In this overview a sarcoma specialist present current evidence on the best way to manage osteosarcoma patients and looks at what has to be done to improve prognosis in this disease, where survival rates have [more]
Conducting clinical trials in people with rare cancers is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach–using Bayesian [more]
Patients are still dying in agony despite concerned efforts over many years to change attitudes towards the use and control of opiates. Could a new initiative, which works with NGOs, governments and policy makers to [more]
Men diagnosed with prostate cancer have a wealth of options on how to proceed, but they can pay a high price if the quality of treatment is substandard. Could delivering all prostate care through specialist [more]
Late toxicities from radiation therapy are frequent in patients with Hodgkin lymphoma and can hamper survival. These late toxicities should decrease with modern radiation therapy, but results are not mature and so the importance of [more]
Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab [more]